ALCLS Share Price Performance
€2.81
1.60 (131.47%)
56.8% undervalued intrinsic discount
€6.50
Fair Value
Price €2.81
AnalystConsensusTarget €6.50
Fair Value€6.50
Share Pricen/a
Cellectis S.A. Stock Price
- 1 Narratives written by author
- 0 Comments on narratives written by author
- 2 Fair Values set on narratives written by author
ALCLS Community Narratives
AN
Fair Value €6.5 56.8% undervalued intrinsic discount
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
Catalysts About Cellectis Cellectis is a clinical stage biotechnology company developing allogeneic CAR T cell therapies and in vivo gene editing solutions for hard to treat cancers and genetic disorders. What are the underlying business or industry changes driving this perspective?Read more
9
users have viewed this narrative0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
€6.5
56.8% undervalued intrinsic discount
Fair Value
Profit Margin
41.15%
Future PE
20.28x
Price in 2028
€7.91
Trending Discussion
Recently Updated Narratives
AN
Allogeneic CAR T Pipeline And AstraZeneca Partnership Will Drive Long-Term Upside
Fair Value: €6.5 56.8% undervalued intrinsic discount
1 followerusers have followed this narrative
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
Snowflake Analysis
Cellectis S.A. Key Details
Last Reported Earnings
Dec 31, 2025
Next Reporting Earnings
n/a
- -0.93
- 100.00%
- -84.92%
- 67.5%
About ALCLS
- Founded
- 1999
- Employees
- 219
- CEO
- WebsiteView website
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications. The company is developing BALLI-01, to evaluate the safety, expansion, persistence, and clinical activities of lasme-cel in patients with r/r ALL; NatHaLi-01, designed to evaluate the safety, expansion, persistence, and clinical activity of eti-cel in patients with relapsed or refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL). It also develops ALPHA3, targets Large B-Cell Lymphoma (LBCL); TRAVERSE, for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (RCC). In addition, the company Melanoma, for treatment of unresectable or metastatic melanoma. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.
